MELAS Syndrome Clinical Trial
Official title:
Phase-1, Dose Finding and Safety Study on L- Citrulline Treatment of Nitric Oxide Deficiency in MELAS
The main purpose of this study is to determine the safest maximum dose of an amino acid, citrulline, which will be used as potential treatment for adult patients with a disorder of energy metabolism called Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). Once established, this dose will be used in a future clinical trial.
The human body is made of many cells and each cell contains many mitochondria. Mitochondria are called the powerhouses of the cell, because they produce the energy needed for a cell to be healthy and function the way it is meant to. Diseases of the mitochondria affect the way the tissues and cells of the body make and use energy, and can affect almost all the different organs of the body like the brain and the muscles. MELAS syndrome is one of the mitochondrial diseases; patients with this disease have different complications including stroke like episodes, headache, muscle weakness, fatigue, and hearing loss. One of the factors contributing to complications seen in patients with MELAS syndrome, in particular the stroke like episodes, is decreased amount of an element called nitric oxide. This element is made in the bodies from an amino acid called arginine. Amino acids are the building blocks of proteins. Proteins make the muscles in the bodies, and they are present in meat, chicken and fish. In this study, the highest acceptable dose of an amino acid called citrulline will be established in participants who have a mitochondrial disorder. Previous research conducted by several groups including Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in patients affected with MELAS. The lack of nitric oxide could cause constriction of blood vessels in the brain making it easier for these patients to have a metabolic stroke. The amino acid citrulline is a foundation for nitric oxide. In earlier studies, the investigator has found that there is more production of nitric oxide in the body when participants affected with MELAS take L-citrulline. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01831934 -
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
|
Phase 4 | |
| Not yet recruiting |
NCT06013397 -
Effectiveness of Ketogenic Diet in MELAS Syndrome
|
N/A | |
| Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
| Completed |
NCT01603446 -
L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome
|
Phase 2 | |
| Completed |
NCT00887562 -
Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
|
Phase 2 | |
| Active, not recruiting |
NCT00068913 -
Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome
|
Phase 2 | |
| Completed |
NCT03888716 -
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
|
Phase 1 | |
| Completed |
NCT04948138 -
Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome
|
N/A | |
| Completed |
NCT03056209 -
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01339494 -
Nitric Oxide Production in MELAS Syndrome
|
Phase 0 | |
| Active, not recruiting |
NCT05255328 -
Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome
|
N/A | |
| Recruiting |
NCT02114554 -
Mitochondrial nt3243 A>G Mutation in Taiwan
|
N/A | |
| Recruiting |
NCT05554835 -
Global Registry and Natural History Study for Mitochondrial Disorders
|
||
| Completed |
NCT01252979 -
Ketones & Mitochondrial Heteroplasmy
|
Phase 0 | |
| Completed |
NCT00004353 -
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
|
N/A |